CLAIM CARD
This synthesis maps 16 included sources on glynac across 6 outcome classes and 17 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.
Evidence grade: exploratory
Contradiction status: none
Publication: 104ef0f2-3c97-42e2-8507-9b6ddf7ebf49
Provenance: Derivation Web chain
Citation Support
source_1Xu 2023source_2Xu 2024source_3Kumar 2020source_4Kumar 2022source_5Kumar 2021